Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of IBI3042 in Healthy Adults and Adults With Overweight or Obesity
NCT07793019Phase 1Recruiting
- Sponsor
- Innovent Biologics
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, randomised trial of IBI3042 in obesity and Overweight (5 arms), sponsored by Innovent Biologics. Primary endpoints: Number of Participants With Adverse Events at 113 days, Number of Participants With Abnormal Physical Examination Findings at 113 days and 3 more. Started Sep 2026; status: recruiting.
02
Drugs
IBI3042
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07793019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07793019.